Clinical Trial: Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07128381) titled 'Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)' on Aug. 13.

Brief Summary: * To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML.

* To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.

Study Start Date: Jan. 31, 2026

Study Type: INTERVENTIONAL

Condition: Myelofibrosis (MF) Chronic Myelomonocytic Leukemia (CMML)

Intervention: DRUG: Axatilimab (SNDX-6352)

Taken orally

DRUG: R...